Mutagenic activity of anticancer agent cis-dichlorodiammine platinum-II
| Autor: | John K. Wiencke, Jaroslav Cervenka, Harold J. Paulus |
|---|---|
| Rok vydání: | 1979 |
| Předmět: |
endocrine system diseases
chemistry.chemical_element Biology Toxicology Chromosomes Mice Bone Marrow In vivo Genetics Animals Humans Distribution (pharmacology) Lymphocytes Mitosis Cells Cultured Chromosome Aberrations Chromosome In vivo analysis Molecular biology In vitro chemistry Cisplatin Chromosome breakage Platinum Sister Chromatid Exchange Mutagens |
| Zdroj: | Mutation Research/Genetic Toxicology. 68:69-77 |
| ISSN: | 0165-1218 |
| DOI: | 10.1016/0165-1218(79)90079-x |
| Popis: | cis -Dichlorodiamminoplatinum-II ( cis -DDP) has been widely used as an anticancer chemotherapeutic agent. The mutagenicity of ( cis -DDP) was investigated in vitro and in vivo using sister-chromatid exchange analysis and the analysis of chromosomal aberrations. Parallel human lymphocyte cultures were incubated with and without the addition of BrdU at 4 concentrations of cis -DDP. Significant increases in SCE rate were observed at 0.25 μg/ml and higher, showing a clear dose-response relation between SCE rate and cis -DDP concentration. A significant increase in chromosome breakage and tetraradial figures was observed in BrdU free cultures treated with cis -DDP again showing a dose dependency. Analysis of the distribution of cells in the first, second and third division in cis -DDP treated cultures demonstrated the depressing effect of the drug on mitotic activity. In vivo analysis of SCE and chromosome aberrations in mouse showed that 13.85 mg/kg i.p. of cis -DDP produces significant increases in the rate of SCE and chromosome aberrations in bone-marrow cells. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|